Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tralokinumab
- Development stage
- Approved
- Lead developer
- LEO Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Tralokinumab is a fully human monoclonal antibody that targets and neutralizes interleukin-13 (IL-13), a cytokine involved in the inflammatory response associated with atopic dermatitis. By binding to IL-13 with high affinity, tralokinumab prevents its interaction with the interleukin-13 receptor alpha 1 (IL-13Rα1) and disrupts downstream signaling pathways that drive inflammation in atopic dermatitis. It is indicated for the treatment of moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 years and older who are candidates for systemic therapy or whose disease is not adequately controlled by topical treatments. Tralokinumab was developed by Leo Pharma and is marketed under the brand names Adtralza (EU/UK) and Adbry (US). It is administered as a subcutaneous injection[1][4][5][7].
- Brand names
- AdtralzaAdbry
- Other names
- tralokinumab-ldrm
02
Targets
IL-13 (Interleukin-13)
Beyond the preview
Go deeper on tralokinumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tralokinumab.